Welcome to our dedicated page for Keros Therapeutics news (Ticker: KROS), a resource for investors and traders seeking the latest updates and insights on Keros Therapeutics stock.
Keros Therapeutics, Inc. develops clinical-stage protein therapeutics for disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins. Company news centers on the rinvatercept (KER-065) program for neuromuscular diseases including Duchenne muscular dystrophy and amyotrophic lateral sclerosis, as well as elritercept for cytopenias in myelodysplastic syndrome and myelofibrosis.
Recurring updates include clinical data presentations, research collaborations, business highlights, financial results, and licensing economics tied to Takeda. Keros also reports governance changes, corporate presentations, portfolio prioritization, and capital actions such as its completed common-stock tender offer and capital return program.
Keros Therapeutics, Inc. (KROS) has appointed Christopher Rovaldi as Chief Operating Officer, effective February 1, 2022. Rovaldi brings over 15 years of experience in developing TGF-β molecules across various diseases. His previous roles include senior leadership positions at Acceleron Pharma, and he has been a consultant since 2018. CEO Jasbir S. Seehra emphasized the importance of Rovaldi's expertise in advancing Keros' pipeline of novel treatments for hematological and musculoskeletal disorders. Keros focuses on addressing high unmet medical needs with its lead candidates KER-050, KER-047, and KER-012.
Keros Therapeutics (Nasdaq: KROS) has re-issued a press release from December 13, 2021, to correct typographical errors regarding its Phase 2 clinical trial of KER-050 for treating anemia in patients with myelodysplastic syndromes (MDS). The corrected document states that two cases of treatment-emergent adverse events, nausea and diarrhea, were related to KER-050. The trial aims to assess KER-050's safety and efficacy in various dosing cohorts, with initial data showing promising erythroid responses in evaluable patients. Keros continues to explore KER-050's potential in MDS and related disorders.
Keros Therapeutics, Inc. (KROS) presented additional data from its Phase 2 clinical trial of KER-050 for myelodysplastic syndromes (MDS) at the ASH Annual Meeting on December 13, 2021. The trial evaluates KER-050's efficacy in treating anemia due to MDS, with 50% of evaluable patients achieving an overall erythroid response. Phase 2 results indicate that KER-050 is generally well-tolerated, with no serious adverse events reported. Keros initiated dosing for Cohort 5 at 5.0 mg/kg, continuing to demonstrate promising advancements in hematologic therapies.
Keros Therapeutics has entered into a licensing agreement with Hansoh Pharma, granting them exclusive rights to develop and commercialize KER-050 in China, Hong Kong, and Macau. Keros will receive a $20 million upfront payment and is eligible for up to $170.5 million in milestone payments, as well as tiered royalties on net sales ranging from low double digits to high teens. This partnership aims to extend Keros' reach into one of the largest pharmaceutical markets globally and focuses on addressing hematological disorders.
Keros Therapeutics, a clinical-stage biopharmaceutical company, announced that its President and CEO, Jasbir S. Seehra, Ph.D., will present at the Piper Sandler 33rd Annual Virtual Healthcare Conference. The presentation is available from November 22, 2021, at 10:00 a.m. ET, and will be archived on Keros' investor website for 90 days. Keros focuses on developing novel treatments for hematological and musculoskeletal disorders, with product candidates including KER-050 for cytopenias and KER-047 for anemia due to iron imbalance.
Keros Therapeutics, Inc. (Nasdaq: KROS) presented preclinical data on KER-012 at the AHA 2021 Scientific Sessions, showing its potential to reduce cardiac dysfunction and remodeling in a pulmonary arterial banding mouse model. The compound demonstrated a cardio-protective mechanism without increasing red blood cells or hemoglobin, suggesting it could treat pulmonary arterial hypertension (PAH) effectively. KER-012 aims to inhibit growth factors to promote bone growth and address conditions like osteoporosis. Initial data from a Phase 1 trial is expected in 2022.
Keros Therapeutics, Inc. (Nasdaq: KROS), a clinical-stage biopharmaceutical company, announced that its CEO, Jasbir S. Seehra, Ph.D., will present at the Jefferies Virtual London Healthcare Conference on November 18, starting at 3:00 a.m. ET. The presentation will be accessible via the provided link and will be archived on Keros’ website for 90 days. Keros focuses on developing treatments for hematological and musculoskeletal disorders, with key products including KER-050 for cytopenias, KER-047 for iron imbalance-related anemia, and KER-012 for bone loss disorders.
Keros Therapeutics, Inc. (Nasdaq: KROS) has announced the presentation of results from a preclinical study of KER-012 at the upcoming American Heart Association 2021 Scientific Sessions, scheduled from November 13-15, 2021. KER-012 is designed to inhibit certain ligands that suppress bone growth and is being evaluated for treating conditions like osteogenesis imperfecta, osteoporosis, and pulmonary arterial hypertension (PAH). The abstract indicates the potential of KER-012 to attenuate cardiac pathology in models of right ventricle overload.
Keros Therapeutics, Inc. (KROS) reported a net loss of $20.3 million for Q3 2021, up from $12.0 million in Q3 2020, primarily due to heightened research and development efforts. R&D expenses soared to $14.8 million, reflecting aggressive pipeline advancement. The company is progressing with a Phase 2 trial of KER-050 for myelodysplastic syndromes and has initiated a Phase 1 trial for KER-012. Keros has $221.3 million in cash, expected to support operations through Q4 2023. A clinical data update will be provided at the 63rd ASH Annual Meeting in December.
Keros Therapeutics (Nasdaq: KROS) has announced four abstracts for presentation at the 63rd American Society of Hematology Annual Meeting from December 11-14, 2021. Key highlights include preliminary results from the Phase 2 trial of KER-050 for treating anemia in myelodysplastic syndromes (MDS). The abstracts feature clinical presentations on KER-050's efficacy, along with preclinical data supporting its therapeutic potential for cytopenias. Keros aims to address significant unmet medical needs in hematological disorders with its innovative solutions.